stockrow
Friday 6 November 2026
Export VERA’s income statement to Excel — free account
Vera Therapeutics, Inc.
VERA Healthcare Biotechnology
- EPS
- −26.7%
- Free cash flow
- −82.5%
- Total debt
- +1.03%
Quarter to June 2026, against a year earlier
30.12
0.02
−0.07%
Follow VERA
Alert me
Vera Therapeutics, Inc. (VERA) Gross margin
Vera Therapeutics, Inc.'s gross margin over the twelve months to 31 March 2023 was 0.00%, down 0.0 percentage points from fiscal 2022 (0.00%). That is below the Biotechnology industry median of 65.2% and below the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Mar 2023 | 0.00% | 0.00 |
| Mar 2022 | 0.00% | 0.00 |
| Dec 2021 | 0.00% | 0.00 |
| Sep 2021 | 0.00% | 0.00 |
| 4 more quarters | Free account |
Gross margin against peers
| Company | Gross margin |
|---|---|
| IMNM Immunome, Inc. compare | 100.0% |
| CLDX Celldex Therapeutics, Inc. compare | 100.0% |
| PVLA Palvella Therapeutics, Inc. compare | 100.0% |
| AUPH Aurinia Pharmaceuticals Inc compare | 90.6% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 89.8% |
| VCEL Vericel Corporation compare | 74.5% |
| ADMA ADMA Biologics Inc compare | 68.5% |
| VERA Vera Therapeutics, Inc. | 0.00% |
| BHVN Biohaven Ltd. compare | 0.00% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue